Deverra

Deverra Therapeutics is a clinical-stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for cancer and infectious diseases. The company holds an exclusive license to a proprietary Notch-mediated stem cell expansion and directed differentiation platform from the Fred Hutchinson Cancer Research Center, built on more than 20 years of federally funded research and multiple clinical trials. Deverra's innovative platform generates a range of unmodified and engineered progenitor and immune cells designed to boost the patient's blood and immune system to eliminate cancer and virally infected cells. The company's team includes pioneers who were the first to demonstrate clinical effectiveness using expanded stem cell therapies and non-HLA matched, universal donor cell therapies.